DSP Healthcare Fund Direct-Growth
Equity: Sectoral-Pharma - Growth (Open ended)
SEBI Riskometer: Very HighCategory: Equity: Sectoral-PharmaBenchmark: BSE Healthcare Total Return IndexCheck Portfolio Overlap →
NAV: ₹48.34-0.01%
22 Oct 2026
Holdings Analysis
Equity, debt and cash allocation snapshot with market cap distribution for DSP Healthcare Fund Direct-Growth.
Market Cap Distribution
Large Cap (30.1%)
Mid Cap (23.0%)
Small Cap (46.9%)
Historical Asset Allocation
| Asset | 30 Sep 2026 | 31 Aug 2026 | 31 Jul 2026 | 30 Jun 2026 | 31 May 2026 | 30 Apr 2026 |
|---|---|---|---|---|---|---|
| Equity | 93.26% | 97.12% | 93.54% | 93.24% | 93.68% | 97.59% |
| Debt | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Others (incl. cash) | 6.74% | 2.88% | 6.46% | 6.76% | 6.32% | 2.41% |
| Commodities | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Real Estate | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Portfolio Snapshot
No. of Securities
33
P/E Ratio
37.83
P/B Ratio
4.71
Top Holding %
8.13%
Top 5 Holdings %
36.01%
Top 10 Holdings %
62.30%
AUM
₹3,750 Cr
Expense Ratio
0.76%
Since Inception
22.09%
Max Drawdown
-0.22%
Alpha
1.68%
Sharpe Ratio
0.96
Top Portfolio Holdings by Weight
Latest portfolio holdings sorted by allocation weight. Includes instrument name, sector, number of shares, market value (₹ Cr) and percentage of net assets. Switch dates or categories using the controls below.
| Instrument | Sector | No. of Shares | Value (Rs. Cr) | Weight | Change |
|---|---|---|---|---|---|
| Ipca Laboratories Ltd. | Healthcare | 15,82,807 | 305.01 | 8.13% | -0.61%↓ |
| Sun Pharmaceutical Industries Ltd. | Healthcare | 15,35,592 | 278.96 | 7.44% | -0.51%↓ |
| Cipla Ltd. | Healthcare | 20,01,379 | 269.39 | 7.18% | -0.17%↓ |
| Sai Life Sciences Ltd. | Healthcare | 16,02,712 | 244.33 | 6.52% | -0.93%↓ |
| Gland Pharma Ltd. | Healthcare | 7,95,267 | 230.58 | 6.15% | 0.17%↑ |
| Apollo Hospitals Enterprise Ltd. | Healthcare | 2,78,729 | 227.6 | 6.07% | -0.40%↓ |
| Alkem Laboratories Ltd. | Healthcare | 3,44,654 | 177.96 | 4.75% | 0.67%↑ |
| Divis Laboratories Ltd. | Healthcare | 1,68,223 | 156.3 | 4.17% | 0.02%↑ |
| Cohance Lifesciences Ltd. | Healthcare | 32,02,999 | 142.21 | 3.79% | -0.02%↓ |
| Alembic Pharmaceuticals Ltd. | Healthcare | 14,42,516 | 119.07 | 3.18% | 0.04%↑ |
| Kovai Medical Center & Hospital Ltd. | Healthcare | 1,76,815 | 106.21 | 2.83% | 0.03%↑ |
| Pfizer Ltd. | Healthcare | 2,63,627 | 102.16 | 2.72% | -0.50%↓ |
| Concord Biotech Ltd. | Healthcare | 7,35,820 | 101.07 | 2.70% | -0.07%↓ |
| Vijaya Diagnostic Centre Ltd. | Healthcare | 6,15,708 | 88.52 | 2.36% | -0.08%↓ |
| Procter & Gamble Health Ltd. | Healthcare | 1,59,288 | 88.61 | 2.36% | -0.04%↓ |
| Indoco Remedies Ltd. | Healthcare | 32,45,682 | 84.93 | 2.26% | 0.20%↑ |
| Thyrocare Technologies Ltd. | Healthcare | 13,41,127 | 71.64 | 1.91% | -0.20%↓ |
| Manipal Health Enterprises Ltd. | Healthcare | 9,80,058 | 69.42 | 1.85% | -1.85%↓ |
| Unichem Laboratories Ltd. | Healthcare | 11,28,668 | 61.57 | 1.64% | 0.00% |
| Syngene International Ltd. | Healthcare | 13,85,126 | 50.6 | 1.35% | 0.04%↑ |
1 / 2
Sector-wise Portfolio Allocation
Equity exposure by sector as a percentage of total net assets, tracked across recent portfolio dates. Identifies concentration risk and sector rotation trends in the fund's holdings.
| Sector | 30 Sep 2026 | 31 Aug 2026 | 31 Jul 2026 | 30 Jun 2026 | 31 May 2026 | 30 Apr 2026 |
|---|---|---|---|---|---|---|
| Healthcare | 91.14% | 95.15% | 91.59% | 91.10% | 91.49% | 95.40% |
| Insurance | 1.02% | 0.99% | 1.08% | 1.20% | 1.31% | 1.35% |
Equity Insights
A detailed look at the equity holdings of this scheme — aggregated scores on value, momentum, quality parameters along with diversification and performance analysis.
Style Analysis
Value score
30.6 / 100
Weighted average Value score is 30.6. This indicates that portfolio is relatively reasonably valued using composite of value measures.
Price Momentum score
72.7 / 100
Weighted average Price Momentum score is 72.7. This indicates that portfolio has average momentum using composite of momentum measures.
Quality score
81.3 / 100
Weighted average Quality score is 81.3. This indicates that portfolio has high quality using composite of quality measures.
QVM score
72.5 / 100
Weighted average QVM score is 72.5. This indicates that portfolio has average QVM score and hence a neutral stance is warranted.
Red Flags
Frequently Asked Questions
What are the top holdings of DSP Healthcare Fund Direct-Growth?
The top holdings of DSP Healthcare Fund Direct-Growth as of 30 Sep 2026 are Ipca Laboratories Ltd. (8.13%), Sun Pharmaceutical Industries Ltd. (7.44%), Cipla Ltd. (7.18%), Others (6.74%), Sai Life Sciences Ltd. (6.52%). These top 5 stocks together account for 36.01% of the total portfolio. You can view the complete holdings breakdown above.
How many stocks does DSP Healthcare Fund Direct-Growth hold in its portfolio?
DSP Healthcare Fund Direct-Growth holds 33 stocks in its portfolio as of 30 Sep 2026. The fund's portfolio size reflects the fund manager's investment approach, a more concentrated portfolio indicates higher conviction bets, while a larger number of holdings suggests a more diversified strategy.
What is the sector allocation of DSP Healthcare Fund Direct-Growth?
As of 30 Sep 2026, DSP Healthcare Fund Direct-Growth's top sector allocations are Healthcare (91.14%), Insurance (1.02%). You can find detailed sector allocation above.
What is the equity and debt allocation of DSP Healthcare Fund Direct-Growth?
As of 30 Sep 2026, DSP Healthcare Fund Direct-Growth has 93.26% allocated to equity, and 0.00% to debt. You can also check the historical trends above.
What is the market cap allocation of DSP Healthcare Fund Direct-Growth?
As of 30 Sep 2026, DSP Healthcare Fund Direct-Growth's market cap allocation is 30.06% in large caps, 23.04% in mid caps, and 46.90% in small caps.
What is the PE ratio of DSP Healthcare Fund Direct-Growth's portfolio?
The portfolio PE ratio of DSP Healthcare Fund Direct-Growth is 37.83 as of 30 Sep 2026. The portfolio PE ratio tells you how expensive or cheap the fund's holdings are relative to their earnings.
What is the credit quality of DSP Healthcare Fund Direct-Growth?
A credit rating breakdown is not available for DSP Healthcare Fund Direct-Growth — its non-equity allocation was 0.00% as of the latest disclosure. This is common when a fund's non-equity holdings are mostly cash or short-term money market instruments, which aren't assigned a credit rating the way bonds are.
When is the latest portfolio disclosure for DSP Healthcare Fund Direct-Growth?
The latest portfolio disclosure for DSP Healthcare Fund Direct-Growth is as of 30 Sep 2026. SEBI requires all mutual funds to disclose their complete portfolio holdings on a monthly basis, typically within 10 days of the end of each month.